EUVIMEDEUVIMED entdecken
Open Access

Malignant peripheral nerve sheath tumors: a report from Children’s Oncology Group study ARST0332

Jacquelyn N Crane iD, Wei Xue, Amira Qumseya, Donald A Barkauskas iD, Khang Chau iD, Serena Y Tan iD, Susan Hiniker iD, Roshni Dasgupta, Rajkumar Venkatramani iD, Sheri L Spunt iD, Aaron R Weiss iD, Theodore W Laetsch iD

JNCI: Journal of the National Cancer Institute · 2026

DOI: 10.1093/jnci/djaf359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2026. Verfasst von Jacquelyn N Crane und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United Stat…. Hauptthemen laut MEDLINE: Nerve Sheath Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Cancer Institute at the National Institutes of Health, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The cornerstone of the treatment of malignant peripheral nerve sheath tumors is surgical resection. Radiation and chemotherapy are variably employed. The optimal treatment remains uncertain, particularly for unresectable or metastatic disease and patients with neurofibromatosis type 1 (NF-1).

Methods

We present data for 58 patients with newly diagnosed malignant peripheral nerve sheath tumors enrolled on the Children’s Oncology Group study ARST0332. Patients were treated with risk-adapted therapy including surgery with or without radiotherapy and ifosfamide and doxorubicin chemotherapy.

Results

Most patients had primary tumors that were greater than 5 cm (86%), deep (95%), and invasive (74%), and 10% had distant metastases. Of the patients, 32 (55%) had germline NF-1, and 26 (45%) did not. Among patients, 31 received neoadjuvant therapy, and 22 were evaluable for response with 5 (23%) attaining an objective response, 10 (45%) stable disease, and 7 (32%) progressive disease. Estimated 5-year event-free survival was 87%, 52%, and 0% for the low- (n = 8), intermediate-, (n = 44), and high-risk (n = 6) patients, respectively. In univariate analysis, event-free survival and overall survival differed by sex, presence or absence of metastatic disease, risk group, and achievement of upfront or delayed R0 and/or R1. There was no difference in event-free survival or overall survival based on germline NF-1 status.

Conclusion

The treatment strategy in ARST0332 achieved excellent outcomes for low-risk malignant peripheral nerve sheath tumors. Patients with high-risk (metastatic) malignant peripheral nerve sheath tumors have poor outcomes, and novel treatments are needed (NCT00346164).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nerve Sheath NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleChildAdolescentChild, PreschoolIfosfamideDoxorubicinInfantNeurofibromatosis 1Young AdultAdultNeoadjuvant TherapyNeurofibrosarcomaCombined Modality TherapyTreatment Outcome

Substanzen

IfosfamideDoxorubicin

Autor:innen und Institutionen

  • Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
  • Department of Biostatistics, College of Public Health and Health Professions and College of Medicine, Gainesville, FL, United States.
  • Department of Population and Public Health Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, CA, United States.
  • Department of Pathology, Stanford University School of Medicine, Stanford, CA, United States.
  • Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, United States.
  • Division of Pediatric General and Thoracic Surgery, Cincinnati Children's Medical Center, University of Cincinnati, Cincinnati, OH, United States.

ORCID-Profile: Jacquelyn N Crane, Donald A Barkauskas, Khang Chau, Serena Y Tan, Susan Hiniker, Rajkumar Venkatramani, Sheri L Spunt, Aaron R Weiss, Theodore W Laetsch

Förderung

  • National Cancer Institute at the National Institutes of Health
  • NCI NIH HHS

Zitieren

APA

Crane, J. N., Xue, W., Qumseya, A., Barkauskas, D. A., Chau, K., Tan, S. Y., Hiniker, S., Dasgupta, R., Venkatramani, R., Spunt, S. L., Weiss, A. R., & Laetsch, T. W. (2026). Malignant peripheral nerve sheath tumors: a report from Children’s Oncology Group study ARST0332. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf359

Vancouver

Crane JN, Xue W, Qumseya A, Barkauskas DA, Chau K, Tan SY, et al. Malignant peripheral nerve sheath tumors: a report from Children’s Oncology Group study ARST0332. JNCI: Journal of the National Cancer Institute. 2026. doi:10.1093/jnci/djaf359

BibTeX
@article{Crane2026,
  author = {Crane, Jacquelyn N and Xue, Wei and Qumseya, Amira and Barkauskas, Donald A and Chau, Khang and Tan, Serena Y and Hiniker, Susan and Dasgupta, Roshni and Venkatramani, Rajkumar and Spunt, Sheri L and Weiss, Aaron R and Laetsch, Theodore W},
  title = {Malignant peripheral nerve sheath tumors: a report from Children’s Oncology Group study ARST0332},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2026},
  doi = {10.1093/jnci/djaf359}
}
Kostenlos starten →